DIO2 CRISPR/Cas9 KO Plasmid (h): sc-402262
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- DIO2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the DIO2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
DIO2 CRISPR/Cas9 KO Plasmid (h) | sc-402262 | 20 µg | $397.00 |
Overview
DIO2 encodes type II iodothyronine deiodinase, an endoplasmic reticulum–associated selenoenzyme that catalyzes outer-ring deiodination of thyroxine (T4) to the active hormone triiodothyronine (T3). By controlling intracellular T3 availability, DIO2 shapes thyroid hormone receptor–dependent transcriptional programs that regulate energy metabolism, thermogenesis, lipid and glucose homeostasis, and differentiation across tissue contexts. DIO2 activity is integrated with redox and selenium biology, including selenoprotein synthesis and oxidative stress responses that influence enzyme stability and turnover. Altered DIO2 expression or function has been linked to metabolic phenotypes and thyroid hormone–responsive pathophysiology, supporting its study in endocrine regulation, obesity-related mechanisms, and tissue-specific thyroid hormone signaling.
DIO2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the DIO2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the DIO2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the DIO2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish DIO2 protein expression.
This CRISPR knockout system enables efficient generation of DIO2-deficient cell models for investigation of DIO2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting DIO2 exon(s) critical for DIO2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple DIO2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by DIO2 CRISPR/Cas9 KO Plasmid (h) and DIO2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the DIO2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by DIO2 HDR Plasmid (h) and DIO2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by DIO2 homology arms to support homology-directed repair at defined DIO2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.